CDKN2A and familial pancreatic carcinoma: In another study of 727 patients with a family history of PDAC, including patients that did not meet the criteria for classification as familial pancreatic cancer, 6 (46.2%) of 13 CDKN2A VUSs identified were functionally deleterious in our assay (Zhen et al., 2015).